T1G3 bladder tumours: The case for conservative treatment

European Urology

Volumn 45, Issue 4, 2004, Pages 401-405

  Turner, William ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

BCG; Bladder neoplasms; Intravesical therapy; Treatment

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BCG VACCINE; DOXORUBICIN; MITOMYCIN C;

BLADDER CANCER; BLADDER TUMOR; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYSTITIS; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SEPSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 1642368890     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.11.008     Document Type: Article

References (44)

1. Heney N.M., Ahmed S., Flanagan M.J., Frable W., Corder M.P., Hafermann M.D.et al. Superficial bladder cancer: progression and recurrence. J. Urol. 130:1983;1083-1086.
2. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S.et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19:2001;666-675.
3. Smith PH, Hall RR. Prognostic factors, treatment options and follow-up of Ta and T1 bladder tumours. In Hall RR, editor. The Clinical Management of Bladder Cancer. London: Arnold; 1997. p. 97-118.
4. Improving Outcomes in Urological Cancers. The Manual. Guidance on Cancer Services. London: National Institute for Clinical Excellence; 2002.
5. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol. 162:1999;74-76.
6. Richards B., Parmar M.K., Anderson C.K., Ansell I.D., Grigor K., Hall R.R.et al. Interpretation of biopsies of "normal" urothelium in patients with superficial bladder cancer. MRC Superficial Bladder Cancer Sub Group. Br. J. Urol. 67:1991;369-375.
7. Witjes J.A., Kiemeney L.A., Schaafsma H.E., Debruyn F.M. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br. J. Urol. 73:1994;172-176.
8. Skinner D.G. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J. Urol. 128:1982;34-36.
9. Herr H.W. High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. Semin. Urol. Oncol. 15:1997;142-146.
10. Oosterlinck W, Lobel B, Jakse G, Malmström P-U, Stöckle M, Sternberg C. Guidelines on Bladder Cancer. Arnhem: European Association of Urology; 2003.
11. Smith J.A. Jr., Labasky R.F., Cockett A.T., Fracchia J.A., Montie J.E., Rowland R.G. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J. Urol. 162:1999;1697-1701.
12. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence. J. Urol. 169:2003;96-100.
13. Fitzpatrick J.M., West A.B., Butler M.R., Lane V., O'Flynn J.D. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J. Urol. 135:1986;920-922.
14. Griffiths T.R., Charlton M., Neal D.E., Powell P.H. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J. Urol. 167:2002;2408-2412.
15. Davis J.W., Sheth S.I., Doviak M.J., Schellhammer P.F. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J. Urol. 167:2002;494-500. [Discussion 501].
16. Jakse G., Hall R., Bono A., Holtl W., Carpentier P., Spaander J.P.et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur. Urol. 40:2001;144-150.
17. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A.et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163:2000;1124-1129.
18. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C.et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 89:2002;671-680.
19. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de Balincourt C., Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J. Urol. 166:2001;476-481.
20. Witjes J.A., van der Meijden A.P., Sylvester L.C., Debruyne F.M., van Aubel A., Witjes W.P. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology. 52:1998;403-410.
21. Sylvester R.J., van der Meijden A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168:2002;1964-1970.
22. Shelley M.D., Kynaston H., Court J., Wilt T.J., Coles B., Burgon K.et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 88:2001;209-216.
23. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;CD003231.
24. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000;CD001986.
25. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169:2003;90-95.
26. Chang S.S., Cookson M.S., Baumgartner R.G., Wells N., Smith J.A. Jr. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J. Urol. 167:2002;2012-2016.
27. Lance R.S., Dinney C.P., Swanson D., Babaian R.J., Pisters L.L., Palmer L.J.et al. Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol. Rep. 8:2001;723-726.
28. Chang S.S., Alberts G., Cookson M.S., Smith J.A. Jr. Radical cystectomy is safe in elderly patients at high risk. J. Urol. 166:2001;938-941.
29. Stroumbakis N., Herr H.W., Cookson M.S., Fair W.R. Radical cystectomy in the octogenarian. J. Urol. 158:1997;2113-2117.
30. Elting L.S., Pettaway C.S., Grossman H.B., Bekele B.N., Saldin K.R., Dinney C.P.N. Relationship between postoperative in-hospital mortality and annual hospital volume of cystectomies: the effect of centers of experience. J. Urol. 169:2003;336.
31. Birkmeyer J.D., Siewers A.E., Finlayson E.V., Stukel T.A., Lucas F.L., Batista I.et al. Hospital volume and surgical mortality in the United States. N. Engl. J. Med. 346:2002;1128-1137.
32. Turner W.H., Bitton A., Studer U.E. Reconstruction of the urinary tract after radical cystectomy: the case for continent urinary diversion. Urology. 49:1997;663-667.
33. Gospodarowicz MK, Warde P, Bristow RG. Radiotherapy for bladder cancer. In Hall RR, editor. The Clinical Management of Bladder Cancer. London: Arnold; 1997. p. 213-35.
34. Morales A., Eidinger D., Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116:1976;180-183.
35. Soloway M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J. Urol. 167:2002;1573-1583.
36. Pansadoro V., Emiliozzi P., de Paula F., Scarpone P., Pansadoro A., Sternberg C.N. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology. 59:2002;227-231.
37. Patard J.J., Rodriguez A., Leray E., Rioux-Leclercq N., Guille F., Lobel B. Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur. Urol. 41:2002;635-641. [Discussion 642].
38. Lamm D.L., Blumenstein B.A., Crawford E.D., Montie J.E., Scardino P., Grossman H.B.et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325:1991;1205-1209.
39. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br. J. Urol. 80:1997;762-765.
40. van der Meijden APM. Bacillus Calmette-Guérin (BCG) for transitional cell carcinoma of the bladder. In Hall RR, editor. The Clinical Management of Bladder Cancer. London: Arnold; 1997. p. 125-43.
41. Slaton J.W., Benedict W.F., Dinney C.P. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology. 57:2001;852-859.
42. Dalbagni G., Rechtschaffen T., Herr H.W. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? J. Urol. 162:1999;708-709.
43. Dalbagni G., Russo P., Sheinfeld J., Mazumdar M., Tong W., Rabbani F. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin - refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol. 20:2002;3193-3198.
44. Merz V.W., Marth D., Kraft R., Ackermann D.K., Zingg E.J., Studer U.E. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br. J. Urol. 75:1995;180-184.